REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Roll-over Study to Allow Continued Access to Ribociclib

11/09/2025 17:05:49


Main Information	
Primary registry identifying number	Protocol number
LBCTR2022095114	CLEE011A2412B
MOH registration number	
Study registered at the country of origin	Study registered at the country of origin: Specify
Yes	
Type of registration	Type of registration: Justify
Prospective	N/A
Date of registration in national regulatory agency	
Primary sponsor	Primary sponsor: Country of origin
Novartis Pharmaceuticals	Novartis Pharmaceuticals
Date of registration in primary registry	Date of registration in national regulatory agency
22/05/2024	Date of registration in national regulatory agency
Public title	Acronym
Roll-over Study to Allow Continued Access to Ribociclib	
Scientific title	Acronym
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis- sponsored Study	
Brief summary of the study: English	
This is an open-label, multi-center, roll-over study to evaluate the long term safety of ribociclib in combination with other drugs in participants who are participating in a Novartis sponsored global study, that has fulfilled requirements for its primary objective(s), and who in the opinion of the Investigator, would benefit from continued treatment.	
Brief summary of the study: Arabic	
تعددة المراكز لتقييم السلامة طويلة المدى لريبوسيكليب بالاشتراك مع أدوية أخرى في المشاركين الذين نوفارتيس، والتي أوفت بمتطلبات هدفها الأساسي (أهدافها)، ومن يعتقد طبيب الدراسة أنه سيستفيد من استمرار العلاج	هذه در اسة تمديد مفتوحة التسمية ومدّ يشاركون في در اسة عالمية تر عاها شركة
Health conditions/problem studied: Specify	
Metastatic Breast Cancer	
Interventions: Specify	
Drug: Ribociclib (Participants continue ribociclib as was administered in f Drug: Letrozole (Participants continue ribociclib in combination with letro Drug: Anastrozole (Participants continue ribociclib in combination with ar Drug: Goserelin (Participants continue ribociclib in combination with gos Drug: Tamoxifen (Participants continue ribociclib in combination with tam	pzole as was administered in their parent study) nastrozole as was administered in their parent study) erelin as was administered in their parent study)

Drug: Fulvestrant (All participants continue ribociclib in combination with fulvestrant as was administered in their parent study)

Key inclusion and exclusion criteria: Inclusion criteria

REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

 Currently participating in a Novartis sponsored global study (parent study) and the parent study has fulfilled its primary objective(s) Must have been receiving treatment with ribociclib for at least 6 cycles in 13. Currently has evidence of clinical benefit as determined by the Investigated 	the parent study	o in combination with other drugs,
Key inclusion and exclusion criteria: Gender	Key inclusion and exclusion c	riteria: Specify gender
Both		
Key inclusion and exclusion criteria: Age minimum	Key inclusion and exclusion c	riteria: Age maximum
18	99	
Key inclusion and exclusion criteria: Exclusion criteria		
 Permanent discontinuation of ribociclib in the parent study Currently has unresolved toxicities for which ribociclib dosing has been in Local access to commercially available ribociclib and reimbursed 	terrupted in the parent study	
Type of study		
Interventional		
Type of intervention	Type of intervention: Specify t	ype
Pharmaceutical	N/A	
Trial scope	Trial scope: Specify scope	
Therapy	N/A	
	. .	
Study design: Allocation	Study design: Masking Open (masking not used)	
	Open (masking not used)	
Study design: Control	Study phase	
Uncontrolled	4	
Study design: Purpose	Study design: Specify purpose)
Treatment	N/A	
Study design: Assignment	Study design: Specify assignm	nent
Single	N/A	
IMP has market authorization	IMP has market authorization:	Specify
Yes, Lebanon and Worldwide	US, EU, and other countries	
Name of IMD	Veen of outbouingtion	Month of authorization
Name of IMP Ribociclib	Year of authorization 2017	1
	2017	
Type of IMP		
Others		
Pharmaceutical class		
highly selective small molecule inhibitor of cyclin-dependent kinases 4 and 6	6 (CDK4/6)	
Therapeutic indication		
Metastatic Breast Cancer		
Therapeutic benefit		
continued treatment to participants who are currently receiving ribociclib		
Study model	Study model: Explain model	
Study model N/A	Study model: Explain model	
1 1// 3		



REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Study model: Specify model N/A	N/A
Time perspective N/A Time perspective: Specify perspective N/A	Time perspective: Explain time perspective N/A
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention None retained	Biospecimen description NA
Target sample size 5	Actual enrollment target size
Date of first enrollment: Type Actual	Date of first enrollment: Date 15/12/2022
Date of study closure: Type Actual	Date of study closure: Date 16/02/2028
Recruitment status Complete	Recruitment status: Specify
Date of completion 03/01/2023	
IPD sharing statement plan Yes	IPD sharing statement description Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Additional data URL

https://clinicaltrials.gov/ct2/show/record/NCT05161195?term=clee011A2412B&draw=2&rank=1

Admin comments





Trial status

Approved

Secondary Identifying Numbers	
Full name of issuing authority	Secondary identifying number
clinicaltrials.gov	NCT05161195

Sources of Monetary or Material Support
Name
Novartis Pharmaceuticals
Name

Secondary Sponsors Name NA

Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Jawad Makarem	Al Chouf	Lebanon	+961 3 484288	jawad.Makarem @awmedicalvilla ge.org	Ain Wazein Medical Village
Scientific	Hind Khairallah	Sin El Fil	Lebanon	+961 1 512002 Ext. 271	Hind.Khairallah@ fattal.com.lb	Khalil Fattal et Fils s.a.l
Public	Nagi El Saghir	Beirut	Lebanon	+961 3 827955	ns23@aub.edu.l b	American University of Beirut Medical Center
Public	Joseph Kattan	Beirut	Lebanon	+961 3 635913	jkattan62@hotm ail.com	Hotel Dieu de France



Centers/Hospitals Involved in the Study				
Center/Hospital nameName of principles investigatorPrinciples investigator specialityEthical app		Ethical approval		
American University of Beirut Medical Center	Nagi El Saghir	Hematology Oncology	Approved	
Ain Wazein Medical Village	Jawad Makarem	Hematology Oncology	Approved	
Hotel Dieu de France	Joseph Kattan	Hematology Oncology	Approved	

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
American University of Beirut Medical Center	05/09/2022	Rami Mahfouz	rm11@aub.edu.lb	+961 (0) 1 350 000 ext:5445
Ain w Zein Medical Village	25/08/2022	Hayat Kamaleddine	irb@awmedicalvillage.org	+961 (0) 5 509 001 ext 2014
Hotel Dieu de France	12/08/2022	Nancy Alam	nancy.alam@usj.edu.lb	+961 (0) 1 421000 ext 2335



Countries of Recruitment
Name
Lebanon
Poland
Singapore
United States of America
Brazil
France
Greece
China
Italy
Japan
Republic of Korea
Mexico
Portugal
South Africa
Spain
Taiwan
Turkey

Health Conditions or Problems Studied		
Condition Code Keyword		
Metastatic Breast Cancer	Malignant neoplasm of breast (C50)	Metastatic Breast Cancer

Interventions		
Intervention	Description	Keyword
ICF, IMP administration, local Labs	ICF, IMP administration, local Labs	ICF, IMP administration, local Labs





Primary Outcomes		
Name	Time Points	Measure
Percentage of participants with treatment-emergent adverse events (AES)	From day of first dose of study medication to 30 days after last dose of study medication, up to 5 years	The percentage of participants with treatment- emergent adverse events will be summarized, including significant adverse events leading to discontinuation, and adverse events leading to dose adjustment

Key Secondary Outcomes		
Name	Time Points	Measure
Clinical benefit rate	Up to 5 years	Percentage of participants with clinical benefit as assessed by the Investigator at scheduled study visits

Trial Results	
Summary results	
Study results globally	
Date of posting of results summaries	Date of first journal publication of results
Results URL link	
Baseline characteristics	
Participant flow	
Adverse events	
Outcome measures	
URL to protocol files	